NCT01958229
- Conditions
- 24-week PCR Negativity of Telbivudine, Blood-Borne Infections, Chronic Disease, +19 more
- Locations
-
- National Taiwan University Hospital Taipei, Taiwan
Clinical trial condition
HBeAg Seroconversion Rate at 52 and 104 Week
Explore clinical trials studying HBeAg Seroconversion Rate at 52 and 104 Week. Study availability and eligibility vary by location and protocol.
1 public trial
0 recruiting studies